Endpoints and New Options for Treatment of Chronic Hepatitis D.

Publication Year: 2021

DOI:
10.1002/hep.32082

PMCID:
PMC9293075

PMID:
34331781

Journal Information

Full Title: Hepatology

Abbreviation: Hepatology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Potential conflict of interest: Dr. Lok advises for and received grants from TARGET. She advises for Ambys, Bristol‐Myers Squibb, CLEAR‐B, GNI, and Eli Lilly. She received grants from Gilead. Dr. Negro consults for, advises for, and received grants from Gilead. He advises for AbbVie and Merck. Dr. Asselah consults for, advises for, is on the speakers’ bureau for, and received grants from Eiger, Gilead, and Myr. Dr. Rizzetto advises for Gilead."

Evidence found in paper:

"P.F. is supported by the Intramural Programs of the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Open Access Funding provided by Universita degli Studi di Torino within the CRUI‐CARE Agreement. [Correction added on 10 May, after first online publication: Open Access Funding provided by Universita degli Studi di Torino within the CRUI‐CARE Agreement funding statement has been added.] Potential conflict of interest: Dr. Lok advises for and received grants from TARGET. She advises for Ambys, Bristol‐Myers Squibb, CLEAR‐B, GNI, and Eli Lilly. She received grants from Gilead. Dr. Negro consults for, advises for, and received grants from Gilead. He advises for AbbVie and Merck. Dr. Asselah consults for, advises for, is on the speakers’ bureau for, and received grants from Eiger, Gilead, and Myr. Dr. Rizzetto advises for Gilead."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025